On November 3, 2025 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported three presentations featuring bezuclastinib, including two oral presentations in NonAdvanced Systemic Mastocytosis (NonAdvSM), at the 67th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) being held December 6-9, 2025 in Orlando, FL. Cogent also announced today plans to describe its novel JAK2 V617F mutant-selective inhibitor as part of a poster presentation at the 2025 ASH (Free ASH Whitepaper) annual meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"On behalf of our clinical trial investigators, Cogent is honored to announce multiple presentations from the SUMMIT trial at this year’s annual ASH (Free ASH Whitepaper) meeting, including two oral presentations which will highlight the exciting results that bezuclastinib demonstrated in NonAdvSM patients," said Andrew Robbins, the company’s President and Chief Executive Officer. "These data support our conviction that based on bezuclastinib’s potential to fundamentally modify the disease in NonAdvSM patients, it has the potential to become the preferred standard of care in this patient population. In addition, at ASH (Free ASH Whitepaper) we look forward to sharing preclinical data from our newest research program, a novel JAK2 V617F mutant-selective inhibitor which we believe has best-in-class potential based on its potency and selectivity."
Bezuclastinib Oral Presentations
Efficacy and safety results from the primary analysis of the pivotal Summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome
Presenter: Lindsay Rein, MD, Associate Professor of Medicine in the Division of Hematologic Malignancies and Cellular Therapy at Duke University
Session Date and Time: December 6, 2025, 9:30 AM – 11:00 AM ET
Presentation Time: 9:45 AM – 10:00 AM ET
Location: – Room – W414CD
The effect of bezuclastinib on the pathobiology of mastocytosis: Changes in BM mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal Summit trial
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Drivers and Mast Cells and Blasts, Oh My! – Insights and Treatments for MPNs and Mastocytosis.
Presenter: Dr. Tracy George, MD, President and Chief Scientific Officer at ARUP Laboratories, Professor of Pathology at the University of Utah School of Medicine
Session Date and Time: December 8, 2025, 4:30 PM – 6:00 PM ET
Presentation Time: 5:00 PM – 5:15 PM ET
Location: – West Hall D2
Bezuclastinib Poster Presentation
Relationship between KIT inhibition by bezuclastinib and effects on disease burden in mouse models of systemic mastocytosis
Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III
Session Date and Time: December 8, 2025, 6:00 PM – 8:00 PM ET
Location: – West Halls B3-B4
JAK2 Poster Presentation
Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor
Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II
Session Date and Time: December 7, 2025, 6:00 PM – 8:00 PM ET
Location: West Halls B3-B4
Full abstracts will be available for online viewing via the ASH (Free ASH Whitepaper) Annual Meeting website: View Source
(Press release, Cogent Biosciences, NOV 3, 2025, View Source [SID1234659249])